Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
Deharo P, Quilici J, Camoin-Jau L, Johnson TW, Bassez C, Bonnet G, Fernandez M, Ibrahim M, Suchon P, Verdier V, Fourcade L, Morange PE, Bonnet JL, Alessi MC, Cuisset T. Deharo P, et al. Among authors: quilici j. JACC Cardiovasc Interv. 2017 Dec 26;10(24):2560-2570. doi: 10.1016/j.jcin.2017.08.044. JACC Cardiovasc Interv. 2017. PMID: 29268886 Free article. Clinical Trial.
Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
Cuisset T, Quilici J, Grosdidier C, Fourcade L, Gaborit B, Pankert M, Molines L, Morange PE, Bonnet JL, Alessi MC. Cuisset T, et al. Among authors: quilici j. Am J Cardiol. 2011 Nov 15;108(10):1411-6. doi: 10.1016/j.amjcard.2011.06.060. Epub 2011 Aug 25. Am J Cardiol. 2011. PMID: 21872198
Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
Cuisset T, Gaborit B, Dubois N, Quilici J, Loosveld M, Beguin S, Loundou AD, Moro PJ, Morange PE, Alessi MC, Dutour A, Bonnet JL. Cuisset T, et al. Among authors: quilici j. Int J Cardiol. 2013 Sep 20;168(1):523-8. doi: 10.1016/j.ijcard.2012.09.214. Epub 2012 Oct 16. Int J Cardiol. 2013. PMID: 23084816
CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome.
Cuisset T, Loosveld M, Morange PE, Quilici J, Moro PJ, Saut N, Gaborit B, Castelli C, Beguin S, Grosdidier C, Fourcade L, Bonnet JL, Alessi MC. Cuisset T, et al. Among authors: quilici j. JACC Cardiovasc Interv. 2012 Dec;5(12):1280-7. doi: 10.1016/j.jcin.2012.07.015. JACC Cardiovasc Interv. 2012. PMID: 23257377 Free article.
Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study.
Deharo P, Pons C, Pankert M, Bonnet G, Quilici J, Grosdidier C, Beguin S, Morange P, Alessi MC, Bonnet JL, Cuisset T. Deharo P, et al. Among authors: quilici j. Int J Cardiol. 2013 Oct 12;168(5):5004-5. doi: 10.1016/j.ijcard.2013.07.121. Epub 2013 Jul 31. Int J Cardiol. 2013. PMID: 23915522 No abstract available.
136 results